Single Ascending Dose Study of NRS 033 in Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2023-11-26
Target enrollment:
Participant gender:
Summary
This is a phase 1, first in human, randomized, double-blind, placebo-controlled, single
ascending dose (SAD) study in healthy adult male and female subjects 18 to 55 years of age,
inclusive.